NRx Pharmaceuticals (NASDAQ:NRXP) today reported its financial results and operational milestones for the full year ended December 31, 2025, highlighting a successful restructuring of its balance sheet and the transition into a revenue-generating entity.
The company reported a significantly improved capital structure following the full conversion of all previously issued convertible debt into common stock, effectively eliminating its debt overhang.
This move, combined with disciplined spending, helped NRx reduce its loss from operations to $16.2 million for the year.
A major operational highlight was the activation of the company’s commercial arm, HOPE Therapeutics.
NRx reported its first-ever clinic revenue from five initial sites, signaling the beginning of a specialized network focused on treating suicidal depression and PTSD.
To accelerate this rollout, NRx announced a nationwide partnership with neurocare AG, which will integrate Transcranial Magnetic Stimulation (TMS) technology into the HOPE clinics.
This "dual-modality" approach—combining TMS with ketamine therapy—is intended to provide a comprehensive suite of interventional psychiatry tools.
On the regulatory front, NRx received a "favorable" signal from the FDA regarding the bioequivalence of its preservative-free ketamine (NRX-100).
This development is critical for the company’s goal of providing a standardized, pharmacy-grade alternative to the compounded ketamine currently used in many clinics.
Based on this feedback and a recent Type C meeting with the agency, NRx anticipates at least one Abbreviated New Drug Application (ANDA) approval as early as the third quarter of 2026.
Furthermore, the company has filed an Investigational New Drug (IND) application for NRX-101, its breakthrough-designated therapy for bipolar depression.
NRx concluded the 2025 fiscal year with $7.8 million in cash, a figure that management believes is sufficient to reach key near-term milestones following the recent debt conversion.